Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
107 results about "Renal Cell Cancers" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoclonal antibodies for treatment of cancer
InactiveUS8946388B2Strong formationStrong proliferationImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseAntiendomysial antibodies
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH +1
Method of Treating Cancer and Bone Cancer Pain
InactiveUS20140179736A1Preventing bone metastasisImprove survivalBiocideNervous disorderMelanomaLung cancer
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
Owner:EXELIXIS INC
Use of myeloid cell biomarkers for the diagnosis of cancer
ActiveUS20120070461A1Diagnosing and prognosing cancerImprove the level ofBiological testingImmunological disordersCancers diagnosisTherapeutic effect
The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Deuterium-Enriched Pyrimidine Compounds and Derivatives
The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.
Owner:DHANOA DALJIT SINGH
Chemo- and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides
InactiveUS20090258089A1Reduce expressionHigh sensitivityHeavy metal active ingredientsApolipeptidesCancer cellAntisense oligodeoxynucleotides
Owner:THE UNIV OF BRITISH COLUMBIA
Method for diagnosing and treating renal cell carcinoma
Objective methods for detecting and diagnosing renal cell carcinoma (RCC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of RCC-associated gene that discriminates between RCC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of renal cell carcinoma, methods of treating renal cell carcinoma and method of vaccinating a subject against renal cell carcinoma.
Owner:ONCOTHERAPY SCI INC
T cell receptors and related materials and methods of use
InactiveUS20090042798A1Peptide/protein ingredientsMammal material medical ingredientsMajor histocompatibilityCancer antigen
The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
Owner:UNITED STATES OF AMERICA
Monoclonal antibodies for treatment of cancer
InactiveUS20110223182A1Minimize adverse effectsStrong formationImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseMelanoma
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1
Application of substituted aryl hydrazone compound serving as anti-tumor necrosis factor inhibitor medicament
ActiveCN101766602AEffective pharmacological activityOrganic active ingredientsAntineoplastic agentsBone marrow fibrosisAnkylosing spondylitis
The invention relates to clinical application of a substituted aryl hydrazone compound and a derivative thereof serving as an anti-tumor necrosis factor inhibitor. A test result shows that the compound has a lower cytotoxicity in animal bodies, so the medical compound is expected to be used as an anti-TNF-alpha and TNF-beta inhibitor in the clinical application and is mainly used for treating some TNF related immunological diseases such as rheumatic arthritis, inflammatory bowel diseases, diabetes, hematosepsis, psoriasis, ankylosing spondylitis and some communicable diseases including HIV. A current TNF related research also shows that the medical compound can be used for treating clinical blood and solid tumor such as myelodysplastic syndrome, myelofibrosis, acute bone marrow cell leucocythemia, acute / chronic graft-versus-host reaction, ovarian cancer, nephrocyte cancer and the like.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Monoclonal antibodies for treatment of cancer
ActiveUS20130071325A1Minimize adverse effectsStrong formationAnimal cellsIn-vivo radioactive preparationsDiseaseMelanoma
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1
Stable axitinib compound
InactiveCN104650034AHigh purityImprove stabilityOrganic active ingredientsOrganic chemistryRenal Cell CancersHigh humidity
The present invention belongs to the technical field of medicine, and particularly relates to an axitinib crystal and a preparation method thereof. The obtained axitinib crystal of the present invention has advantages of high purity and good stability, wherein the moisture absorption weight increase of the axitinib crystal is not significant even under the high humidity condition. The present invention further relates to applications of a composition using the axitinib crystal in treatment of advanced renal cell carcinoma.
Owner:TIANJIN HANKANG PHARMA BIOTECH
Monoclonal antibodies for treatment of cancer
ActiveUS9216218B2Strong formationStrong proliferationAnimal cellsHybrid immunoglobulinsDiseaseAntiendomysial antibodies
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH +1
Dual-targeting fusion protein and encoding gene and application thereof
The present invention discloses dual-targeting fusion protein CFmDEC capable of mediating a type 5 adenovirus vector to be specifically bound with a surface molecule DEC205 of a dendritic cell; and by utilizing a gene fragment sig-tG250-Fc-IRES-GM-CSF-B7.1(25) of a multi-targeted anti-renal cancer compound antigen, an anti-renal cell carcinoma adenovirus vaccine-Ad5-tG250FcGB is constructed with a type 5 replication-deficient adenovirus as a vector. The dual-targeting fusion protein CFmDEC is capable of enhancing the antitumor effect of the renal cell cancer adenovirus vaccine Ad5-tG250FcGB, is effectively combined with the adenovirus, improves the DCs-targeted ability of the adenovirus vaccine, and can induce higher specific antitumor immune response in a human body and suppress the growth of renal cell cancer.
Owner:ACADEMY OF MILITARY MEDICAL SCI
Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
InactiveUS7727714B2Sugar derivativesMicrobiological testing/measurementRenal Cell CancersCancer cell
Owner:ONCOTHERAPY SCI INC
Theranostic and diagnostic methods using sparc and hsp90
InactiveUS20140018254A1Suppressing peroxidase activityShorten the timeMicrobiological testing/measurementLibrary screeningInterdigitating dendritic cell sarcomaHSP90 Heat-Shock Proteins
Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect expression levels of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma.
Owner:VON HOFF DANIEL D +1
Hypoxia-inducible protein 2 (hig 2), a diagnostic marker for clear cell renal cell carcinoma
InactiveUS20100204060A1Microbiological testing/measurementLibrary screeningCancer cellRenal Cell Cancers
Owner:ONCOTHERAPY SCI INC
Method for predicting prognosis of renal cell carcinoma
InactiveUS20150118681A1Sure easyHigh sensitivityMicrobiological testing/measurementCpG siteRenal Cell Cancers
In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.
Owner:NAT CANCER CENT
Methods and materials for treating renal cell carcinoma
ActiveUS20120230989A1Avoid unnecessary treatment attempt unnecessaryAvoid unnecessary unnecessary patient sufferingBiocideImmunoglobulins against growth factorsTreatment optionsOncology
This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14+ cells and proceeding with a cancer treatment option (e.g., a renal cell carcinoma treatment option) based on the presence, absence, or level of CD14+ cells present within the tumor or peritumoral tissue are provided.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Thienothio compound and application thereof
The invention belongs to the technical field of medicines and relates to a thienothio compound and an application thereof. A thienothiapyran compound comprises derivatives and pharmaceutically applicable salt of the thienothiapyran compound, and has a structural formula; the thienothiapyran compound and the pharmaceutically applicable acid addition salt of the thienothiapyran compound can be combined with conventional drugs or are individually used as epidermal growth factor tyrosine kinase inhibitors for treating related diseases of epidermal growth factor receptor signaling dysregulation, such as small cell lung cancers, squama cancers, glandular cancers, large cell cancers, colorectal cancers, breast cancers, ovarian cancers, renal cell cancers and bronchial asthma.
Owner:SHENYANG PHARMA UNIVERSITY
Compositions and methods of treating renal cell cancer
Owner:DANA FARBER CANCER INST INC +1
Indole carboxamide compounds and use thereof
The invention belongs to the technical field of medicine and relates to indole carboxamide compounds and a use thereof. The indole carboxamide compounds comprise derivatives of indole carboxamide and pharmaceutically acceptable salts thereof. The indole carboxamide compounds have a general formula shown in the description. R1, R2 and R3 are defined in the claims and the specification. The indole carboxamide compounds and pharmaceutically acceptable acid salts can be used as epidermal growth factor tyrosine kinase inhibitors for treatment on epidermal growth factor receptor transfer disorder associated diseases such as small cells lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, colorectal cancer, breast cancer, ovarian cancer and renal cell carcinoma.
Owner:SHENYANG PHARMA UNIVERSITY
High-transfer kidney clear cell cancer cell system for the Han nationality
InactiveCN101508972AMicrobiological testing/measurementMicroorganism based processesClear cellMetastatic phenotype
The invention discloses a method for constructing the Hans highly metastatic renal clear cell carcinoma cell line HiMet-ccRCC, CCTCC-C200909 with metastatic phenotype in the Hans renal clear cell carcinoma vertebrae metastasis. The invention adopts culture in vitro to construct a human renal clear cell carcinoma cell line having high metastatic potential with vertebrae metastasis of renal clear cell carcinoma patients as tumor source for constructing the line. Tests show that the inventive cell line has the typical characteristics of tumor cell lines, and is capable of leading NOD-SCID mice to generate stable metastasis and being used as the construction of cell model for the screening preparation detection and prophylaxis of Hans renal cell carcinoma pharmaceuticals.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Chimeric antigen receptors against axl or ror2 and methods of use thereof
PendingCN110177808APolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorRenal Cell Cancers
The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and / or Ror2, such as renal cell carcinoma.The present disclosure provides cells genetically modified to produce the CARs.
Owner:F1 ONCOLOGY INC
Novel translocation companion of TFEB as well as detection primer and application thereof
ActiveCN109022433AImprove the detection rateImprove accuracyMicrobiological testing/measurementDNA/RNA fragmentationNucleotideTFEB
The invention discloses a novel translocation companion of TFEB as well as a detection primer and application thereof. The novel translocation companion of the TFEB is an ACTB-TFEB gene subjected to translocation, gene fusion happens between an exon 3 of ACTB and an exon 2 of a TFEB gene, and the novel translocation companion of the TFEB comprises a nucleotide sequence as shown in SEQ ID NO.3. ThePCR primers for detecting the novel translocation companion of the TFEB are composed of ACTB-E3-F as shown in SEQ ID NO.1 and TFEB-E2-R as shown in SEQ ID NO.2. The invention further discloses application of an agent for detecting the translocation companion of the TFEB in preparing an ACTB-TFEB translocation renal cell carcinoma diagnosis agent. A novel tool is provided for fast and accurately diagnosing an ACTB-TFEB translocation tumor.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
Application of PPAR delta inhibitor combined immunotherapy drug in preparation of antitumor drugs
PendingCN112972688AReduce proliferationReduce functionAntibody ingredientsImmunoglobulinsProstate cancerStomach cancer
The invention relates to application of a PPAR delta inhibitor combined immunotherapy drug in preparation of antitumor drugs. The immunotherapy drug is an immune agonist or an immune checkpoint inhibitor. The tumors are preferably melanoma, breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colon cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancer, renal cell cancer or gastric cancer. The medicine disclosed by the invention is remarkable in anti-tumor effect, high in targeting property and very small in side effect.
Owner:JILIN UNIV FIRST HOSPITAL
Immunofluorescence kit for E-Cadherin expression of peripheral blood circulating tumor cells of patient with renal cell carcinoma, and detection method
InactiveCN111679077AReal-time detectionReduce lossesBiological material analysisBiological testingTumor cellsNeedle biopsy
The invention belongs to the technical field of molecular biology, and particularly relates to an immunofluorescence kit for detecting E-Cadherin expression of peripheral blood circulating tumor cellsof a patient with renal cell carcinoma, and a detection method. The immunofluorescence kit comprises a diluents 45 mL, decolorizing liquid 1 mL, a staining solution A 0.5 mL, a staining solution B 1mL, methanol 200 mu l, 2% PFA 200 mu l, 10% goat serum 100 mu l, a primary antibody suspension 100 mu l composed of mouse anti-CK, rat anti-CD45 and rabbit anti-E-Cadherin, a secondary antibody suspension 100 mu l composed of fluorescently-labeled goat anti-mouse, fluorescently-labeled goat anti-rat and fluorescently-labeled goat anti-rabbit, and a DAPI tablet. According to the detection method provided by the invention, the E-Cadherin expression condition of the patient with later-period or relapse renal cell carcinoma can be detected without acquiring a tissue specimen through needle biopsy.The immunofluorescence kit belongs to minimally invasive technology and can realize real-time detection.
Owner:山东凯歌智能机器有限公司
Culture medium for culturing recurrent renal cell carcinoma organoid and application of culture medium
InactiveCN114574443ALow costImprove the success rate of cultivationCell dissociation methodsDrug screeningRenal Cell CancersCancer drugs
The invention discloses a culture medium for a recurrent renal cell carcinoma tumor organoid and a culture method of the culture medium. By adjusting the content of each component of the culture medium, the organoid culture of a tumor sample of the recurrent renal cell carcinoma can be realized, the success rate of the culture of the organoid of the renal cell carcinoma is greatly improved, the culture period is shortened, the culture cost is reduced, and a foundation is laid for revealing the pathogenesis of the recurrent renal cell carcinoma and screening anti-cancer drugs.
Owner:上海诺典生物科技有限公司
Renal cell carcinoma treatment
InactiveCN1367702AOrganic active ingredientsPeptide/protein ingredientsParanasal Sinus CarcinomaTumor response
The present invention discloses a method of treating RCC patients who have not received or received treatment to obtain at least a partial tumor response, including administering a therapeutically effective amount of pegylated interferon alpha, such as pegylated alpha-2b, said interferon Use as a sole treatment or in combination with an effective amount of IL-2.
Owner:SCHERING AG
Application of decitabine and oxaliplatin in preparation of combination drug for treating renal cell carcinoma
ActiveCN104147036AIncreased sensitivityGood synergyAntineoplastic agentsHeavy metal compound active ingredientsPharmaceutical medicineOncology
The invention provides an application of decitabine and oxaliplatin in preparation of a combination drug for treating renal cell carcinoma, wherein the molar concentration ratio of decitabine to oxaliplatin is 1:5-1:8, and the combination drug is prepared from decitabine, oxaliplatin and pharmaceutically acceptable auxiliary materials. In-vivo and in-vitro experimental researches prove that decitabine has an obvious synergistic effect on oxaliplatin in treatment of renal cell carcinoma, and the result expands the clinical application scope of decitabine and oxaliplatin. The combination drug provided by the invention can enhance accumulation of oxaliplatin in tumor cells of a renal cell carcinoma mouse model, and at the same time, enhances the sensitivity of the renal cell carcinoma mouse model to oxaliplatin.
Owner:ZHEJIANG UNIV
Biomarker, method for searching disease-related gene, and renal cancer marker
InactiveCN109906382AMicrobiological testing/measurementBiological material analysisRenal Cell CancersNormal tissue
Owner:JAPANESE FOUND FOR CANCER RES +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com